# This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

> **NCT03165240** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 62 (actual)

## Conditions studied

- Diabetic Nephropathies

## Interventions

- **DRUG:** BI 690517
- **DRUG:** Eplerenone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03165240
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-05
- **Primary completion:** 2020-04-16
- **Final completion:** 2020-05-07
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03165240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03165240, "This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03165240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*